COVID-19 treatment is still being developed by different medical experts and researchers across the globe. A new study showed that remdesivir and plasma might be the best treatment for the global coronavirus pandemic. However, other drugs are needed to make an ultimate cure.
According to NBC News, convalescent plasma is another key treatment for COVID-19. The acting director of the Biomedical Advanced Research and Development Authority (BARDA), Gary Disbrow, informed a Senate Appropriates subcommittee during a hearing on Thursday, July 2, that the demand for the antibody-rich blood product from patients who recovered from COVID-19 has been high, with an estimated 25,000 patients already transfused in the United States.
On the other hand, a new drug candidate called Epo is on its way. According to Medical Express's latest report, the researchers at the Max-Planck Institute of Experimental Medicine in Gottingen claimed that the doping agent Epo, a medication for anemia also known as Erythropoietin, can also be efficient at eliminating the novel coronavirus.
Patients can be protected from long-term neurological effects when the SARS-CoV-2 virus attacks the brains. The study shows the positive effects of anemia medicine in initial case studies.
According to the report, a randomized clinical trial is currently planned by the researchers to investigate the effects of Epo treatment in coronavirus patients systematically. BMC Part of Springer Nature published the results of the study on June 16.
Also Read: Is COVID-19 Weakening? Study Says Virus Mutates up to 6x More Infectious Now
